Novartis signs macrocyclic deal with Unnatural Products for $100M upfront

Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...

AI Summary: Novartis has committed $100 million upfront to partner with Unnatural Products, acquiring access to a macrocyclic peptide platform designed to reach challenging protein targets. The deal accelerates Novartis’ efforts to expand into next‑generation peptide therapeutics and bolsters its early R&D pipeline with technology aimed at previously “undruggable” targets.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio / 2 months

Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 3 months

AstraZeneca Secures Pan‑KRAS Inhibitor Deal with Jacobio Pharma / 5 months

Biogen announces $5.6B acquisition of Apellis Pharma / 1 month

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months

Servier to acquire Day One Biopharma for $2.5B / 2 months

Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 2 months